Table 1.

Duloxetine clinical trials in fibromyalgia and clinical measures utilized.

Study	Acute Duration, wks	Dose	Duloxetine (n)	Placebo (n)	Clinical Measures
I⁷	12	60 mg	104	103	BDI, BPI, FIQ, PGI-I, SDS, SF-36, TP
II⁸	12	60 mg	118	120	BPI, HAMD, FIQ, PGI-I, SDS, SF-36, TP
		60 mg	116
III⁹	15	20 mg	79	144	BDI, BPI, HAMD,
		60 mg	150		EQ5D, FIQ, MFI, PGI-I,
		120 mg	147		SDS, SF-36, TP
IV¹⁰	28	60/120 mg	162	168	BDI, BPI, HAMD, EQ5D, FIQ, MFI, PGI-I, SDS, SF-36, TP

BDI: Beck Depression Inventory; BPI: Brief Pain Inventory; EQ5D: EuroQol Questionnaire 5 Dimensions; FIQ: Fibromyalgia Impact Questionnaire; MFI: Multidimensional Fatigue Inventory; PGI-I: Patient Global Impression of Improvement; SDS: Sheehan Disability Scale; SF-36: Medical Outcomes Study Short-Form 36; TP: tender point dolorimetry; HAMD: Hamilton Depression Rating Scale.